A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC

Key Points

• Osimertinib resistance is effectively targeted using a combined strategy of EGFR-MET bispecific antibody and HER3 ADC.
• The combination shows improved cancer cell inhibition when compared to standard treatments, with significant impact on tumor growth.
• Observational analysis focuses on the synergistic effects of dual targeting, particularly addressing resistance pathways in NSCLC.
• The findings support this novel approach as a potential alternative, needing further exploration in clinical settings.